Icon of the Instituts for Quality and Efficiency in Health Care

Report

Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

Status
Status: Commission completed
Project no.
A20-60
Last updated

Report documents

  1. Extract of the final report

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 1 MB, EN, not accessible
    Download file : Extract of the final report (PDF document, 1 MB, EN, not accessible)

  2. Final report

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 5 MB, DE, not accessible
    Download file : Final report (PDF document, 5 MB, DE, not accessible)

  3. Documentation of comments on the preliminary report

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 3 MB, DE, not accessible
    Download file : Documentation of comments on the preliminary report (PDF document, 3 MB, DE, not accessible)

  4. Preliminary report

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 5 MB, DE, not accessible
    Download file : Preliminary report (PDF document, 5 MB, DE, not accessible)

  5. Report plan

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 447 kB, DE, not accessible
    Download file : Report plan (PDF document, 447 kB, DE, not accessible)

  6. Documentation of comments on the report plan

    Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis

    published on
    Document type
    PDF document, 897 kB, DE, not accessible
    Download file : Documentation of comments on the report plan (PDF document, 897 kB, DE, not accessible)

Press releases

Multiple sclerosis: Hardly any evidence for good patient care

Many questions about the treatment of relapsing-remitting MS remain unanswered in IQWiG’s final report due to a lack of health care-relevant study data: only 3 out of 10 drugs analysed showed a benefit. English translation now available.
Press release

Project details

Project no.
A20-60
Commission
Commission awarded on 16.07.2020 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

The current version 2.1 of of the report plan replaces version 2.0 published on 2021-08-20.

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page